Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1948 in Advanced Solid Tumors
NCT03565445Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2018
- Primary completion
- Mar 2023
- Countries
- 9
01
Overview
Phase 1, open-label trial of ASP1948 in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC) and 5 more (3 arms), sponsored by Astellas Pharma. Primary endpoints: Number of Participants with Dose Limiting Toxicities at 28 days, Number of Participants with Adverse Events and 4 more. Started Jul 2018; status: completed.
02
Drugs
ASP1948
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)metastatic castration-resistant prostate cancer (mCRPC)ovarian cancer
Beyond the preview
Go deeper on NCT03565445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565445.